GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » Deferred Policy Acquisition Costs

Phio Pharmaceuticals (FRA:44R3) Deferred Policy Acquisition Costs


View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Phio Pharmaceuticals (FRA:44R3) Business Description

Traded in Other Exchanges
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.